Reported covered position: LD, Rep. Jon Porter
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicaid VBPs for Patients Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: THE MCMANUS GROUP
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Increasing Prescription Drug Competition Act
Client: AVADEL PHARMACEUTICALS · Firm: THE MCMANUS GROUP
Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2024 · first_quarter · 1T
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Source: Senate LDA
| zimmer biomet | 17 | 2020–2023 |
| ALNYLAM PHARMACEUTICALS | 16 | 2020–2023 |
| AMGEN | 16 | 2020–2023 |
| EMD SERONO, INC. | 16 | 2020–2023 |
| GENENTECH | 16 | 2020–2023 |
| GRAIL, Inc. | 16 | 2020–2023 |
| PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) | 16 | 2020–2023 |
| HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) | 15 | 2020–2023 |
| INFUSION PROVIDERS ALLIANCE | 15 | 2020–2023 |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 15 | 2020–2023 |
| ORCHARD THERAPEUTICS NORTH AMERICA | 13 | 2021–2024 |
| AMERICAN OCCUPATIONAL THERAPY ASSOCIATION | 12 | 2021–2023 |
| LARGE UROLOGY GROUP PRACTICE ASSOCIATION | 12 | 2021–2023 |
| PTC THERAPEUTICS, INC. | 12 | 2021–2023 |
| WEX HEALTH | 12 | 2021–2023 |
| AVADEL PHARMACEUTICALS | 10 | 2022–2024 |
| ALKERMES, INC. | 9 | 2021–2023 |
| INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) | 9 | 2022–2023 |
| ALLERGAN, INC. | 2 | 2020 |
| IVX HEALTH | 2 | 2020 |
| RED FLAT NICKEL CORPORATION | 2 | 2020 |
Increasing Prescription Drug Competition Act
Client: AVADEL PHARMACEUTICALS · Firm: THE MCMANUS GROUP
Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act)
Access and reimbursement of medical devices in Medicare program. Issues related to H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act, relating to maximum fair price negotiation. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R.1557 - BID Act of 2023 H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. H.R.1557 - BID Act of 2023, requiring the Secretary of Health and Human Services to submit a report on the interoperability of medical devices. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Issues related to H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act, relating to maximum fair price negotiation. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R.1557 - BID Act of 2023 H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program. Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. H.R.1557 - BID Act of 2023, requiring the Secretary of Health and Human Services to submit a report on the interoperability of medical devices. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including CMS-1744-IFC,CMS-5531-IFC, CMS-1853-P, and H.R.1694 - Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Emergency Care Improvement Act
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: THE MCMANUS GROUP
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Strengthening Medicare for Patients and Providers Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875, S.2880 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.4189 - CONNECT for Health Act of 2023. Support of S. 1592 - Occupational Therapy Mental Health Parity Act. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. Advocate for introduction of legislation that would establish occupational therapy as a qualifying Medicare home health service. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act
Strengthening Medicare for Patients and Providers Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Strengthening Medicare for Patients and Providers Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
Strengthening Medicare for Patients and Providers Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 3284, the Providers and Payers COMPETE Act. H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Strengthening Medicare for Patients and Providers Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to ASP and H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act
Strengthening Medicare for Patients and Providers Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Support of S. 1592 - Occupational Therapy Mental Health Parity Act. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform.
Strengthening Medicare for Patients and Providers Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 H.R. 3284, the Providers and Payers COMPETE Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 H.R.2880 - Protecting Patients Against PBM Abuses Act Continued expansion of Telehealth services including in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Strengthening Medicare for Patients and Providers Act
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
Access and appropriate reimbursement of Part B drugs in clinic setting Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Issues related to MACRA reform. HR 2474, the Strengthening Medicare for Patients and Providers Act. Advocating for access to biosimilars.
Strengthening Medicare for Patients and Providers Act
Client: AMERICAN OCCUPATIONAL THERAPY ASSOCIATION · Firm: THE MCMANUS GROUP
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.4189 - CONNECT for Health Act of 2023. Support of S. 1592 - Occupational Therapy Mental Health Parity Act. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act
Strengthening Medicare for Patients and Providers Act
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Issues related to MACRA reform. Advocating for access to biosimilars. Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative); HR 5391, Protecting Patient Access to Cancer and Complex Therapies Act.
Strengthening Medicare for Patients and Providers Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526).
Policies to remove barriers to physician prescribing decisions including in H.R.2630/S.652 - Safe Step Act.
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, S.2973 - Modernizing and Ensuring PBM Accountability Act.
Safe Step Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to implementation and enforcement of the CY 2023 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule with Comment Period CMS 1772-FC.
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Policies to remove barriers to physician prescribing decisions including in H.R.2630/S.652 - Safe Step Act.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Advocating for access to biosimilars. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. S. 652/HR 2630, Safe Step Act S. 1375/HR 830, HELP Copays Act Issues related to White Bagging. Access to Alzheimer's Disease therapies.
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Safe Step Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Safe Step Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Safe Step Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Medicaid VBPs for Patients Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: THE MCMANUS GROUP
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Medicaid VBPs for Patients Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 2666 - Medicaid VBPs for Patients (MVP) Act S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Medicaid VBPs for Patients Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: THE MCMANUS GROUP
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Medicaid VBPs for Patients Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: THE MCMANUS GROUP
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Medicaid VBPs for Patients Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: THE MCMANUS GROUP
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
American Innovation and R&D Competitiveness Act of 2023
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: GENENTECH · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS INC. · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673, S.866 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs Act
American Innovation and R&D Competitiveness Act of 2023
Client: GENENTECH · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023 S.314 - Cost Recovery and Expensing Acceleration to Transform the Economy and Jumpstart Opportunities for Businesses and Startups Act S.866 - American Innovation and Jobs Act
American Innovation and R&D Competitiveness Act of 2023
Client: GENENTECH · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs Act
American Innovation and R&D Competitiveness Act of 2023
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS INC. · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023
American Innovation and R&D Competitiveness Act of 2023
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023 S.866 - American Innovation and Jobs Act
American Innovation and R&D Competitiveness Act of 2023
Client: PTC THERAPEUTICS INC. · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Pharmacy Benefits Manager Accountability Act
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.1375/H.R.830 - HELP Copays Act.
Protecting Patients Against PBM Abuses Act
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Issues related to MACRA reform. Advocating for access to biosimilars. Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative); HR 5391, Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patients Against PBM Abuses Act
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, H.R. 5378: Lower Costs, More Transparency Act.
Protecting Patients Against PBM Abuses Act
Client: GILEAD SCIENCES, INC. · Firm: THE MCMANUS GROUP
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, H.R. 5378: Lower Costs, More Transparency Act. S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.1375/H.R. 830 HELP Copays Act
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, H.R. 5378: Lower Costs, More Transparency Act. S.1375/H.R. 830 HELP Copays Act. H.R.5539 - ORPHAN Cures Act S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Protecting Patients Against PBM Abuses Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, S.2973 - Modernizing and Ensuring PBM Accountability Act.
Protecting Patients Against PBM Abuses Act
Client: ALNYLAM PHARMACEUTICALS · Firm: THE MCMANUS GROUP
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R. 5539 - ORPHAN Cures Act H.R.2880 - Protecting Patients Against PBM Abuses Act Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Protecting Patients Against PBM Abuses Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 2666 - Medicaid VBPs for Patients (MVP) Act S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Protecting Patients Against PBM Abuses Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 H.R. 3284, the Providers and Payers COMPETE Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 H.R.2880 - Protecting Patients Against PBM Abuses Act Continued expansion of Telehealth services including in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Protecting Patients Against PBM Abuses Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 3284, the Providers and Payers COMPETE Act. H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Protecting Patients Against PBM Abuses Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act/S.2333 - Pandemic and All-Hazards Preparedness and Response Act Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.1375/H.R. 830 HELP Copays Act
Protecting Patients Against PBM Abuses Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Protecting Patients Against PBM Abuses Act
Client: ALNYLAM PHARMACEUTICALS · Firm: THE MCMANUS GROUP
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. H.R. 5539 - ORPHAN Cures Act
To amend title XVIII of the Social Security Act to require each off-campus outpatient department of a provider to include a unique identifier on claims for items and services, and to require providers with a department of a provider to submit to the Centers for Medicare & Medicaid Services an attestation with respect to each such department.
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. H.R. 5539 - ORPHAN Cures Act
Providers and Payers COMPETE Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Providers and Payers COMPETE Act
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Providers and Payers COMPETE Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Providers and Payers COMPETE Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Providers and Payers COMPETE Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 3284, the Providers and Payers COMPETE Act. H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Providers and Payers COMPETE Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 H.R. 3284, the Providers and Payers COMPETE Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 H.R.2880 - Protecting Patients Against PBM Abuses Act Continued expansion of Telehealth services including in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Providers and Payers COMPETE Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Fairness for Patient Medications Act
Client: INFUSION PROVIDERS ALLIANCE · Firm: THE MCMANUS GROUP
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act/S.2333 - Pandemic and All-Hazards Preparedness and Response Act Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. S.1375/H.R. 830 HELP Copays Act
340B Transparency Act
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
340B Transparency Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542.
340B Transparency Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.1375/H.R. 830 HELP Copays Act. Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542.
340B Transparency Act
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVADEL PHARMACEUTICALS via THE MCMANUS GROUP
2024 · first_quarter · 1T
Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to PPBM transparency, including, H.R.5378 - Lower Costs, More Transparency Act
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Advocating for access to biosimilars. HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. S. 652/HR 2630, Safe Step Act S. 1375/HR 830, HELP Copays Act Issues related to White Bagging. Access to Alzheimer's Disease therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023 S.866 - American Innovation and Jobs Act
Issues related to Ethylene Oxide (EtO) sterilization.
Access and reimbursement of medical devices in Medicare program. Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related health savings accounts (HSAs) and individual coverage health reimbursement arrangements (ICHRAs) including in H.R.3799 - CHOICE Arrangement Act. H.R. 5688, the Bipartisan HSA Improvement Act of 2023 H.R. 5687, the HSA Modernization Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS INC. via THE MCMANUS GROUP
2023 · fourth_quarter · 4T
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Issues related to research and development tax amortization in H.R. 2673, S.866 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs Act
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act). Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.1375/H.R. 830 HELP Copays Act. Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542.
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 2666 - Medicaid VBPs for Patients (MVP) Act S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC).
Issues related to Ethylene Oxide (EtO) sterilization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 H.R. 3284, the Providers and Payers COMPETE Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 H.R.2880 - Protecting Patients Against PBM Abuses Act Continued expansion of Telehealth services including in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Education and awareness related to COVID-19 therapeutics. Issues related to H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act and S.2333 - Pandemic and All-Hazards Preparedness and Response Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. S.1375/H.R. 830 HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023 S.314 - Cost Recovery and Expensing Acceleration to Transform the Economy and Jumpstart Opportunities for Businesses and Startups Act S.866 - American Innovation and Jobs Act
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. S. 2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act H.R.2880 - Protecting Patients Against PBM Abuses Act H.R.5547/S. 476 - Maintaining Investments in New Innovation Act
EMD SERONO, INC. via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.2880 - Protecting Patients Against PBM Abuses Act
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542.
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.2880 - Protecting Patients Against PBM Abuses Act H.R. 3284, the Providers and Payers COMPETE Act. H.R.6683 - Preserving Seniors Access to Physicians Act of 2023
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs Act
Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVADEL PHARMACEUTICALS via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
H.R. 5378: Lower Costs, More Transparency Act. H.R.4822 - Health Care Price Transparency Act of 2023 H.R.3561 - PATIENT Act of 2023 S.3548 - Health Care Prices Revealed and Information to Consumers Explained Transparency Act
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023. Site neutrality provisions including in H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875, S.2880 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.4189 - CONNECT for Health Act of 2023. Support of S. 1592 - Occupational Therapy Mental Health Parity Act. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. Advocate for introduction of legislation that would establish occupational therapy as a qualifying Medicare home health service. H.R. 4878, the EMPOWER Act, S.2459 - Enabling More of the Physical and Occupational Workforce to Engage in Rehabilitation Act
S.2840 - Bipartisan Primary Care and Health Workforce Act S.462/H.R. 4933 - Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.1375/H.R.830 - HELP Copays Act. Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542.
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act H.R.2880 - Protecting Patients Against PBM Abuses Act
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2023 · fourth_quarter · Q4
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R. 5539 - ORPHAN Cures Act H.R.2880 - Protecting Patients Against PBM Abuses Act Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023
Access and reimbursement of medical devices in Medicare program. Issues related to H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act, relating to maximum fair price negotiation. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R.1557 - BID Act of 2023 H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related health savings accounts (HSAs) and individual coverage health reimbursement arrangements (ICHRAs)including in H.R.3799 - CHOICE Arrangement Act. H.R. 5688, the Bipartisan HSA Improvement Act of 2023 H.R. 5687, the HSA Modernization Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS INC. via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act). Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, H.R. 5378: Lower Costs, More Transparency Act. S.1375/H.R. 830 HELP Copays Act. H.R.5539 - ORPHAN Cures Act S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R. 2666 - Medicaid VBPs for Patients (MVP) Act
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2023 · third_quarter · Q3
Implementation of surprise billing reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2023 · third_quarter · Q3
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2023 · third_quarter · Q3
Implementation of surprise billing reform.
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2023 · third_quarter · Q3
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. H.R.1557 - BID Act of 2023, requiring the Secretary of Health and Human Services to submit a report on the interoperability of medical devices. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2023 · third_quarter · Q3
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) via THE MCMANUS GROUP
2023 · third_quarter · Q3
Education and awareness related to COVID-19 therapeutics. Issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act and S.2333 - Pandemic and All-Hazards Preparedness and Response Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2023 · third_quarter · Q3
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Issues related to MACRA reform. Advocating for access to biosimilars. Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative); HR 5391, Protecting Patient Access to Cancer and Complex Therapies Act.
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2023 · third_quarter · Q3
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, S.2973 - Modernizing and Ensuring PBM Accountability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2023 · third_quarter · Q3
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, H.R. 5378: Lower Costs, More Transparency Act. S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.1375/H.R. 830 HELP Copays Act
Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act/S.2333 - Pandemic and All-Hazards Preparedness and Response Act Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.1375/H.R. 830 HELP Copays Act
EMD SERONO, INC. via THE MCMANUS GROUP
2023 · third_quarter · Q3
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act, H.R. 5378: Lower Costs, More Transparency Act.
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2023 · third_quarter · Q3
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to ASP and H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2023 · third_quarter · Q3
Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVADEL PHARMACEUTICALS via THE MCMANUS GROUP
2023 · third_quarter · Q3
Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2023 · third_quarter · Q3
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023. Site neutrality provisions including in H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
H.R. 5378: Lower Costs, More Transparency Act,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2023 · third_quarter · Q3
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act, H.R.4189 - CONNECT for Health Act of 2023. Support of S. 1592 - Occupational Therapy Mental Health Parity Act. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform. H.R. 4878, the EMPOWER Act
Continued expansion of telehealth services in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act. S.2840 - Bipartisan Primary Care and Health Workforce Act S.462/H.R. 4933 - Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Q3
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2764/H.R. 5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.1375/H.R.830 - HELP Copays Act.
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2023 · third_quarter · Q3
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act. H.R. 5539 - ORPHAN Cures Act
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via THE MCMANUS GROUP
2023 · third_quarter · 3T
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. Issues related to the reauthorization of the SUPPORT (H.R. 4531, the SUPPORT for Patients and Communities Reauthorization Act)
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to the reauthorization of the SUPPORT Act for Patients and Communities Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2023 · second_quarter · Q2
Issues related to research and development tax amortization in H.R. 2673 - American Innovation and R&D competitiveness Act of 2023
Access and reimbursement of medical devices in Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2023 · second_quarter · Q2
Issues related to industrial banks.
Issues related health savings accounts (HSAs) and individual coverage health reimbursement arrangements (ICHRAs)including in H.R.3799 - CHOICE Arrangement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS INC. via THE MCMANUS GROUP
2023 · second_quarter · Q2
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act). Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2023 · second_quarter · Q2
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R. 2666 - Medicaid VBPs for Patients (MVP) Act
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. S.1375/H.R. 830 HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2023 · second_quarter · Q2
Implementation of surprise billing reform including in Division BB, Title I of H.R. 133 - Consolidated Appropriations Act, 2021 and CMS-9909-IFC and CMS-9908-IFC.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2023 · second_quarter · Q2
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2023 · second_quarter · Q2
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Issues related to FY2024 Medicare Hospital Inpatient Prospective Payment System (IPPS)(CMS-1785-P)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2023 · second_quarter · Q2
Continued expansion of Telehealth services including in H.R. 3857 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2023 · second_quarter · Q2
Access and appropriate reimbursement of Part B drugs in clinic setting Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Issues related to MACRA reform. HR 2474, the Strengthening Medicare for Patients and Providers Act. Advocating for access to biosimilars.
Policies to remove barriers to physician prescribing decisions including in H.R.2630/S.652 - Safe Step Act.
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2023 · second_quarter · Q2
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R.4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2023 · second_quarter · Q2
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; S.2085- A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2023 · second_quarter · Q2
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. S.1375/H.R. 830 HELP Copays Act
Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2023 · second_quarter · Q2
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2023 · second_quarter · Q2
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. H.R. 3284, the Providers and Payers COMPETE Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Patient access to colonoscopy procedures in commercial insurance. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act.
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2023 · second_quarter · Q2
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVADEL PHARMACEUTICALS via THE MCMANUS GROUP
2023 · second_quarter · Q2
Increased access to narcoleptic medication (S.574 - Increasing Prescription Drug Competition Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2023 · second_quarter · Q2
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023. Site neutrality provisions including in H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2023 · second_quarter · Q2
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act.
Implementation of surprise billing reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2023 · second_quarter · Q2
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act/S.2333 - Pandemic and All-Hazards Preparedness and Response Act Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. S.1375/H.R. 830 HELP Copays Act
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) via THE MCMANUS GROUP
2023 · second_quarter · Q2
Education and awareness related to COVID-19 therapeutics. Issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act and S.2333 - Pandemic and All-Hazards Preparedness and Response Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Q2
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. S.1375/H.R.830 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2023 · second_quarter · Q2
Access to DME-infused drugs in the home. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for S.476 Maintaining Investments in New Innovation Act
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via THE MCMANUS GROUP
2023 · second_quarter · Q2
Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to the reauthorization of the SUPPORT Act for Patients and Communities Act.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. Issues related to the reauthorization of the SUPPORT for Patients and Communities Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2023 · second_quarter · Q2
Continued expansion of telehealth services in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act.
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of telehealth services in H.R. 3875 - Expanded Telehealth Access Act and the Telehealth Modernization Act. Support of S. 1592 - Occupational Therapy Mental Health Parity Act. Support of H.R.2474 - Strengthening Medicare for Patients and Providers Act. Issues related to MACRA reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program.
Issues related to Certificates to Foreign Government (CFG) documents and device shortage reporting.
Issues related to proposed corporate tax changes in P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2023 · first_quarter · Q1
Issues related to industrial banks.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS INC. via THE MCMANUS GROUP
2023 · first_quarter · Q1
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs. Supporting the designation of October 23 as "AADC Deficiency Awareness Day".
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376-Inflation Reduction Act of 2022. Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act). Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Issues related to research & development tax amortization.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2023 · first_quarter · Q1
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Access and reimbursement in Medicare Parts B & D. Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2023 · first_quarter · Q1
Implementation of surprise billing reform including in Division BB, Title I of H.R. 133 - Consolidated Appropriations Act, 2021 and CMS-9909-IFC and CMS-9908-IFC.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization including in Newborn Screening Saves Lives Reauthorization Act of 2021.
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2023 · first_quarter · Q1
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers, including CMS-1744-IFC,CMS-5531-IFC, CMS-1853-P, and H.R.1694 - Emergency Care Improvement Act.
Implementation of surprise billing reform including in Division BB, Title I of H.R. 133 - Consolidated Appropriations Act, 2021 and CMS-9909-IFC and CMS-9908-IFC.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2023 · first_quarter · Q1
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act. Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to implementation and enforcement of the CY 2023 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule with Comment Period CMS 1772-FC.
Access and reimbursement of Part B drugs in Medicare. Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act. Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022. Support for site neutrality policies. Support for Sec. 4113 - Advancing Telehealth Beyond COVID-19 included in H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328).
INVIVYD (FORMERLY KNOWN AS ADAGIO THERAPEUTICS)) via THE MCMANUS GROUP
2023 · first_quarter · Q1
Education and awareness related to COVID-19 therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFUSION PROVIDERS ALLIANCE via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies.
Policies to remove barriers to physician prescribing decisions including in H.R.2630/S.652 - Safe Step Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and reimbursement in Medicare Part D and Part B. Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via THE MCMANUS GROUP
2023 · first_quarter · Q1
Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2023 · first_quarter · Q1
Medicare Part D reform. Provisions included in Title I - Subtitle B of Public Law No: 117-169/H.R. 5376 - Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2023 · first_quarter · Q1
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Medicare Parts B and D reform. Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2023 · first_quarter · Q1
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Provisions included in Title I-Subtitle B of PL. 177-169/H.R. 5376 - Inflation Reduction Act of 2022.
General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and Telehealth Modernization Act. Support for site neutrality policies. Provisions included in Title I - Subtitle B of Public Law No: 117-169/H.R. 5376 - Inflation Reduction Act of 2022. Support for Sec. 4113 - Advancing Telehealth Beyond COVID-19 included in H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328).
Continued expansion of Telehealth services including in the Expanded Telehealth Access Act and the Telehealth Modernization Act Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Safe Step Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access to autologous cellular immunotherapies in Medicare Part B. Provisions included in Title I - Subtitle B of PL. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVADEL PHARMACEUTICALS via THE MCMANUS GROUP
2023 · first_quarter · Q1
Increased access to narcoleptic medication (S.574 - Increasing Prescription Drug Competition Act)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2023 · first_quarter · Q1
Increased patient access and reimbursement to procedures in ambulatory surgical centers including in H.R. 972/S. 312 - Outpatient Surgery Quality and Access Act of 2023. Introduction to MedPAC Commissioner nominee.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OCCUPATIONAL THERAPY ASSOCIATION via THE MCMANUS GROUP
2023 · first_quarter · Q1
Continued expansion of Telehealth services in the Expanded Telehealth Access Act and the Telehealth Modernization Act.
Continued access to occupational therapy services including in the Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act. Continued expansion of Telehealth services in Expanded Telehealth Access Act and the Telehealth Modernization Act. Support introduction of the Occupational Therapy Mental Health Parity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Q1
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Provisions included in Title I - Subtitle B of PL. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2023 · first_quarter · Q1
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies(DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable MedicalEquipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas;Extension of Timeline for Final Rule Publication (CMS-1687-RCN). Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act of 2022. Issues related to access and coverage in Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via THE MCMANUS GROUP
2023 · first_quarter · Q1
Access and reimbursement in Medicare Parts B & D. Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2022 · fourth_quarter · Q4
Access and reimbursement of medical devices in Medicare program.
Issues related to Certificates to Foreign Government (CFG) documents and device shortage reporting. Provisions included in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.
Issues related to proposed corporate tax changes in P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2022 · fourth_quarter · Q4
Issues related to industrial banks including H.R. 5912 - Close the ILC Loophole Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS INC. via THE MCMANUS GROUP
2022 · fourth_quarter · Q4
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs. H.Res.742 - Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376-Inflation Reduction Act of 2022. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2022 · fourth_quarter · Q4
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
Access and reimbursement in Medicare Parts B & D. Provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act/S.2333 - Pandemic and All-Hazards Preparedness and Response Act Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542. S.1375/H.R. 830 HELP Copays Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Support for site neutrality policies. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to maximum fair price in S. 2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE